Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …

The incidence and mortality of lung cancer rank top three of all cancers worldwide.
Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) …

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following
molecular profiling has dramatically changed the way advanced adenocarcinoma is treated …

While significant advancements have been made in the available therapies for metastatic
non-small cell lung cancer (NSCLC), acquired resistance remains a major barrier to …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

Lung cancer accounts for a quarter of all cancer deaths. Non-small cell lung cancer
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …

Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy
and in some cases lower toxicity than conventional treatment. Although targeted …

The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

The identification of driver mutations in epidermal growth factor receptor, anaplastic
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …